Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (140)
The pivotal programs are STEP (semaglutide for weight management, The New England Journal of Medicine , 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)
No tiered qualification puzzle, just transparent rates
Research from the Endocrine Society shows that pathways implicated in addiction also contribute to pathological overeating
STEP-2 (N=1,210 adults with type 2 diabetes) confirmed that even the 1.0 mg dose of semaglutide produces clinically significant metabolic changes within 8-12 weeks, which is well within the timeframe that ovulatory function may normalize in previously anovulatory women